Core Insights - Elicio Therapeutics published follow-up data from the Phase 1 AMPLIFY-201 study in Nature Medicine, demonstrating that over two-thirds of participants with T cell responses exceeding the antitumor efficacy threshold had significantly reduced risks of relapse or death [1][5][11] Group 1: Study Results - At a median follow-up of 19.7 months, median overall survival (OS) increased from 16.33 months to 28.94 months [5][11] - A 77% reduction in the risk of death and an 88% reduction in the risk of relapse were associated with T cell responses above the efficacy threshold [5][11] - Direct ex vivo mKRAS-specific T cell responses were observed in 84% of patients, with both CD4+ and CD8+ T cell responses in 71% of patients [6][11] - Antigen-spreading was observed in 67% of patients, indicating a broader immune response beyond the targeted mKRAS antigens [11] Group 2: Clinical Implications - The updated data supports the potential of the AMP platform to provide durable benefits to pancreatic ductal adenocarcinoma (PDAC) patients in the adjuvant setting [3][5] - The final event-driven disease-free survival (DFS) analysis for the ongoing Phase 2 AMPLIFY-7P study is anticipated in Q4 2025 [5][6] Group 3: Technology and Future Directions - Elicio's AMP platform aims to enhance the education, activation, and amplification of cancer-specific T cells, potentially leading to improved clinical outcomes compared to conventional vaccination strategies [9][14] - ELI-002 targets the most common KRAS mutations, which drive approximately 25% of all solid tumors, and is being studied in patients with mKRAS-positive pancreatic and colorectal cancers [9][12] - Future plans include expanding ELI-002 to other indications, such as mKRAS-positive lung cancer [9][12]
Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients